Business Wire

QPS Announces New Global Clinical Research Operations Leadership

Share

QPS, a leading global contract research organization (CRO), is pleased to announce new clinical research operations leadership. This new clinical leadership will further align the existing global medical affairs, regulatory affairs, data services, and clinical operations units with the existing successful QPS Phase I clinics. The enhanced global capabilities will help QPS satisfy the need for agility, flexibility, and speed in the quickly evolving global drug development community.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240620868635/en/

QPS Holdings, LLC corporate headquarters in Delaware Technology Park in Newark, Delaware. This location is also the QPS Bioanalysis Laboratory Center of Excellence for small and large molecule drug development. (Photo: Business Wire)

“This addition of Mr. Derek Grimes to the QPS Global Leadership Team will enhance our ability to collaborate across business units to offer comprehensive custom-built clinical development programs to better address a future dominated by Biologics and Advanced Therapy programs and a demand for accelerated clinical trials,” said Benjamin Chien, Chairman, President and CEO of QPS.

Mr. Derek Grimes, QPS Executive Vice President and Global Head of Clinical Research is a distinguished executive with 26 years of leadership experience in healthcare and clinical research across both academic and private institutions. He has played a pivotal role in developing complex healthcare and clinical research organizations and has been the operational lead on several hundred clinical research programs for academic and industry-based organizations. Grimes’ extensive experience and contributions to the field have made him a respected leader in clinical research and healthcare management. Most recently, Grimes served as the Senior Vice President of Clinical Operations at Frontage Laboratories, where he led the operations for the Clinical Services Division.

“I am excited to join the team and look forward to getting started. There is huge potential in the QPS full-service global CRO offering and enhanced alignment of leadership across the units will benefit our clients tremendously,” says Grimes.

In 2022, QPS announced a full transformation to a globally structured organization leading to seamless delivery of preclinical, bioanalytical, and clinical trial services around the world. At the same time, the organization formalized its medical affairs and regulatory affairs departments and onboarded new senior leaders for those teams. This enhanced structure has benefited our global customers, as our teams now more closely collaborate across all global regions. The addition of Grimes to this organization will further solidify QPS’ ability to serve Biotech and Pharmaceutical clients around the world.

ABOUT QPS HOLDINGS, LLC

QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,100+ employees in the US, Europe, and Asia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, and turnkey laboratories and facilities. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers. For more information, visit www.qps.com or email info@qps.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240620868635/en/

Contacts

QPS CONTACT:
Name: Gabrielle Pastore
Phone: 1-302-635-4290
Email: Gabrielle.Pastore@qps.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Esri Press Book by Jack Dangermond Explores Creating a Better Future through Modern GIS17.7.2024 20:46:00 CEST | Press release

Esri, the global leader in location intelligence, today announced the publication next month of The Power of Where: A Geographic Approach to the World's Greatest Challenges. Written by Esri president Jack Dangermond with a dedicated Esri team and numerous contributors, this important new book explores the geographic approach—a way of solving problems using spatial analysis to perceive and understand patterns ranging from wildlife migration and rising seas to urban planning and food production. According to Dangermond, sustainability begins with geography. "I believed this when we started Esri, and I'm even more convinced today," says Dangermond. "GIS [geographic information system technology] provides a platform for addressing problems, exploring alternatives, designing solutions, and sharing them in a visual way that inspires action." The Power of Where shows through maps and stories how the growing GIS community is facing humanity's big challenges, including climate change, hunger, w

Egle Therapeutics to share preclinical data for its first autoimmune disease program, EGL-003, with an oral presentation at the 2024 Promise of Interleukin-2 Therapy Meeting17.7.2024 18:00:00 CEST | Press release

Egle Therapeutics, a biotechnology company focused on advancing the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, will deliver an oral presentation at The Promise of Interleukin-2 Therapy meeting taking place in Paris from September 4th to 7th, 2024. The presentation, entitled “EGL-003, a novel IL-2 mutein to selectively expand and activate regulatory T cells and improve therapeutic efficacy in autoimmune disease”, will show evidence that EGL-003, a non-targeted Fc-fused IL-2 agonist mutein, selectively binds to regulatory T cells (Treg) and induces Treg IL-2 signaling. The resulting increase of Treg frequencies was observed in vitro and in different mouse models. Accordingly, EGL-003 significantly improved clinical, macroscopic, and histological parameters in a DSS-induced colitis mouse model with expansion of tissue-resident Tregs. EGL-003 is the first drug candidate being developed for treatment of autoimmune diseases in Egle’s pipeline and h

Mouser Electronics Unlocks Game-Changing Human-Machine Interfaces in Latest Content Series17.7.2024 17:11:00 CEST | Press release

Mouser Electronics, Inc., the authorized global distributor with the newest electronic components and industrial automation products, today released the latest installment of its Empowering Innovation Together (EIT) technology series, exploring the unique attributes of human-machine interfaces (HMI) for everyday devices and industrial applications. With the evolution of HMI, engineers are blending intuitive, user-centric designs with cutting-edge technologies to introduce a host of novel capabilities. In this series, Mouser takes a deeper look at the future technological and societal impact of HMIs across our devices, cars, houses, and each other. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240717572923/en/ Enter the world of HMI and Human Factors, where engineers and researchers delve into the psychological, physiological, and ergonomic aspects of designing interfaces for human-machine interaction to optimize user experi

LambdaTest Integrates Allure Reports with HyperExecute for Enhanced Test Reporting17.7.2024 17:00:00 CEST | Press release

LambdaTest, a leading cloud-based unified testing platform, is thrilled to announce the integration of Allure Reports with HyperExecute. This new integration aims to transform the test reporting landscape, offering a more streamlined, detailed, and visually appealing way to manage and review test results. Allure Framework is a versatile, lightweight, multi-language test reporting tool that provides a concise representation of tested functionalities through visually appealing web reports. It facilitates the easy extraction of valuable information for all stakeholders involved in the development process, enhancing collaboration and efficiency. For teams already utilizing Allure reports, the integration with HyperExecute allows for the seamless generation of consolidated Allure reports for each job. These reports are accessible through the report section of the HyperExecute dashboard, centralizing test insights and simplifying management. Additionally, HyperExecute users can enhance their

LTIMindtree Delivers 2.6% QoQ USD Revenue Growth in CC17.7.2024 16:40:00 CEST | Press release

LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, announced its consolidated results today for the first quarter ended June 30, 2024, as approved by its Board of Directors. “While the environment remains unchanged, fiscal 25 started on a positive note for us with Q1FY25 revenue of USD 1.1 billion, registering a 2.5% QoQ and 3.5% YoY revenue growth in USD terms. Our Q1FY25 EBIT expanded to 15% and order inflow remained stable at USD 1.4 billion. Our top 3 industry verticals and our largest geography have performed well sequentially. This is attributed to a measured uptick in IT spending for critical initiatives with clients balancing innovation and fiscal prudence.” -Debashis Chatterjee, Chief Executive Officer and Managing Director Key financial highlights: Quarter ended June 30, 2024 In USD: - Revenue at $1,096.2 million (+2.5% Q-o-Q / +3.5% Y-o-Y) - Net profit at $136.1 million (+2.8% Q-o-Q / -2.9% Y-o-Y) In INR: - Revenue at Rs 91,42

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye